American Society of Hematology

SHERPA: Blue

People

  1. Derkach
    Derkach
  2. Hultcrantz
    Hultcrantz
  3. Lesokhin
    Lesokhin
  4. Shah
    Shah
  5. Maclachlan
    Maclachlan
  6. Mailankody
    Mailankody
  7. Tan
    Tan
  8. Usmani
    Usmani
  9. Giralt
    Giralt
  10. Hassoun
    Hassoun

Groups

  1. Biostatistics Service (86)
  2. Epidemiology and Biostatistics (86)
  3. Population Sciences Research Program (86)
  4. Hematologic Malignancies, Division of (81)
  5. Department of Medicine (80)
  6. Center for Hematologic Malignancies (79)
  7. Hematology-Oncology Fellows (64)
  8. GME, Medicine (50)
  9. Graduate Medical Education (50)
  10. Sloan Kettering Institute Postdocs (42)
Search Within
  1. "Andriy Derkach"
Formats
  1. Meeting Abstract (71)
  2. Journal Article (14)
  3. Research Letter (1)
Groups
  1. Biostatistics Service (86)
  2. Epidemiology and Biostatistics (86)
  3. Population Sciences Research Program (86)
  4. Hematologic Malignancies, Division of (81)
  5. Department of Medicine (80)
  6. Center for Hematologic Malignancies (79)

More Groups

People
  1. Andriy Derkach (86)
  2. Alexander Lesokhin (35)
  3. Malin Hultcrantz (35)
  4. Urvi Shah (35)
  5. Carlyn Rose Tan (31)
  6. Kylee Maclachlan (31)

More People

Years
  1. 2025 (4)
  2. 2024 (27)
  3. 2023 (22)
  4. 2022 (14)
  5. 2021 (6)
  6. 2020 (13)
Publications
  1. Blood (75)
  2. Blood Advances (11)

Results (86)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
    Journal Article

    Adegbite, B.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing
    Research Letter

    Tan, C. R.; Wang, A.; Nemirovsky, D.; Derkach, A.; Shekarkhand, T.; Hamadeh, I.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Patients with AML and an IDH2-R172 mutation exhibit a unique initial response to intensive chemotherapy induction
    Journal Article

    Yisraeli Salman, M.; Terry, A. R.; Derkach, A.; Nemirovsky, D.; Chin, K. K.; Valtis, Y. K.; Boussi, L.; Spivey, T.; Xiao, W.; Famulare, C.; more...
    Blood Advances (2025)

    Fulltext@MSK | Save
  • Defining 2 biologically and clinically distinct groups in acute leukemia with a mixed phenotype
    Journal Article

    Galera, P.; Dilip, D.; Derkach, A.; Chan, A.; Zhang, Y.; Persaud, S.; Mishra, T.; Kramer, K.; Kathpalia, M.; Liu, Y.; more...
    Blood (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin, nirogacestat and pomalidomide for patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Hultcrantz, M.; Hassoun, H.; Tan, C. R.; Korde, N.; Lesokhin, A. M.; Hashmi, H.; Maclachlan, K. H.; Rajeeve, S.; Shah, U. A.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
    Meeting Abstract

    Bewersdorf, J. P.; Derkach, A.; Zeidan, A. M.; Stein, E. M.; Mauro, M. J.; Podoltsev, N. A.; Rampal, R.
    Blood (2024)

    Fulltext@MSK | Save
  • Long-term follow-up of real-world teclistamab therapy for relapsed/refractory multiple myeloma from the IMWG Immunotherapy Working Group Committee
    Meeting Abstract

    Tan, C. R.; Asoori, S.; Nemirovsky, D.; Derkach, A.; Brunaldi, L.; Popat, R.; Lau, C.; Kastritis, E.; Martínez-Lopez, J.; Bansal, R.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML
    Meeting Abstract

    Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G.; Borge, P.; Geyer, M. B.; Goldberg, A. D.; Haque, T.; Park, J. H.; Roeker, L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Racial differences in proportion of myeloma cases attributable to modifiable risk factors in the United States, 2016-21
    Meeting Abstract

    Anuraj, A.; Rath, D.; Derkach, A.; Usmani, S. Z.; Shah, U. A.
    Blood (2024)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma- Interim efficacy results of a randomized clinical trial
    Meeting Abstract

    Rajeeve, S.; Derkach, A.; Devlin, S. M.; Santos, J.; Przemielewska, A.; Sood, T.; Maclachlan, K. H.; Hashmi, H.; Tan, C. R.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save